Related Experiment Video
Updated: Oct 6, 2025
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Targeted Extracellular Vesicles Delivered Verrucarin A to Treat Glioblastoma
Kai Chen1, Yingnan Si1, Jia-Shiung Guan2
1Department of Biomedical Engineering, University of Alabama at Birmingham (UAB), 1825 University Blvd, Birmingham, AL 35294, USA.
Abstract:
Glioblastomas, accounting for approximately 50% of gliomas, comprise the most aggressive, highly heterogeneous, and malignant brain tumors. The objective of this study was to develop and evaluate a new targeted therapy, i.e., highly potent natural compound verrucarin A (Ver-A), delivered with monoclonal antibody-directed extracellular vesicle (mAb-EV). First, the high surface expression of epidermal growth factor receptor (EGFR) in glioblastoma patient tissue and cell lines was confirmed using immunohistochemistry staining, flow cytometry, and Western blotting. mAb-EV-Ver-A was constructed by packing Ver-A and tagging anti-EGFR mAb to EV generated from HEK293F culture. Confocal microscopy and the In Vivo Imaging System demonstrated that mAb-EV could penetrate the blood-brain barrier, target intracranial glioblastoma xenografts, and deliver drug intracellularly. The in vitro cytotoxicity study showed IC50 values of 2-12 nM of Ver-A. The hematoxylin and eosin staining of major organs in the tolerated dose study indicated minimal systemic toxicity of mAb-EV-Ver-A. Finally, the in vivo anti-tumor efficacy study in intracranial xenograft models demonstrated that EGFR mAb-EV-Ver-A effectively inhibited glioblastoma growth, but the combination with VEGF mAb did not improve the therapeutic efficacy. This study suggested that mAb-EV is an effective drug delivery vehicle and natural Ver-A has great potential to treat glioblastoma.
Insights
This study developed a targeted therapy using natural compound verrucarin A (Ver-A) delivered via antibody-directed extracellular vesicles (mAb-EV) for glioblastoma treatment. The therapy showed minimal toxicity and effectively inhibited tumor growth in preclinical models.
Area of Science:
- Neuro-oncology
- Drug Delivery Systems
- Natural Product Chemistry
Background:
- Glioblastomas are aggressive, heterogeneous brain tumors with limited treatment options.
- Targeted therapies are crucial for improving glioblastoma treatment efficacy.
- Extracellular vesicles (EVs) show promise as drug delivery vehicles for brain tumors.
Purpose of the Study:
- To develop and evaluate a novel targeted therapy for glioblastoma using verrucarin A (Ver-A) encapsulated in monoclonal antibody-directed extracellular vesicles (mAb-EV).
- To assess the efficacy and safety of mAb-EV-Ver-A in preclinical glioblastoma models.
Main Methods:
- Confirmed high epidermal growth factor receptor (EGFR) expression in glioblastoma tissues and cell lines.
- Constructed anti-EGFR mAb-tagged EVs loaded with Ver-A (mAb-EV-Ver-A).
- Evaluated BBB penetration, tumor targeting, in vitro cytotoxicity, systemic toxicity, and in vivo anti-tumor efficacy.
Main Results:
- mAb-EV successfully penetrated the blood-brain barrier and targeted intracranial glioblastoma xenografts.
- Ver-A exhibited high in vitro cytotoxicity against glioblastoma cells (IC50: 2-12 nM).
- mAb-EV-Ver-A demonstrated minimal systemic toxicity and effective inhibition of glioblastoma growth in vivo.
Conclusions:
- Monoclonal antibody-directed extracellular vesicles (mAb-EV) serve as an effective drug delivery system for glioblastoma.
- The natural compound verrucarin A (Ver-A) holds significant therapeutic potential for treating glioblastoma.
More Related Videos
09:02Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
08:50Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics
Published on: August 16, 2024
